An improved process for the preparation of Metaxalone, wherein reacting 3,5-dimethyl phenol with 3-chloro-l,2-propane diol in presence of a base; isolating 3-(3,5-dimethylphenoxy) propane- 1,2-diol; reacting 3-(3,5-dimethylphenoxy)propane-l,2-diol with urea in presence of polyalkylene glycol to obtain Metaxalone; op...

The present invention relates to an improved process for the preparation of Entacapone (!) of formula (I). comprising of knoevenagal condensation of 3,4-dihydroxy-5-nitrobenzaldehyde of formula (II) with N, N-diethyl cyanoacetamide of formula (III) in an aprotic non-polar solvent, containing catalytic amount of a...

The present invention relates to one pot synthesis of Fexofenadine starting from the l-acetoxy-2-methyl-2-phenyl. propane or l-acetoxy-2-methyl-2-[4-[4-chloro-1-oxy-butyl)phenyl]-propane, without isolating the intermediates to obtain Fexofenadine, which is optionally converted to the pharmaceutically acceptable salt...

The sustained release compositions comprising Nitazoxanide and/or its pharmaceutically acceptable salts thereof.

A pharmaceutical composition comprising Milnacipran or its pharmaceutically acceptable salts and a superdisintegrant in amount of 0.1% to 50%, preferably 2% to 20% by weight of the composition.

The present invention relates to novel polymorph of Agomelatine and a process for the preparation thereof

The present invention relates to a pharmaceutical composition comprising Orlistat including its salts, solvates, polymorphs, racemic mixtures, enantiomers, and mixtures thereof and a process for preparing the formulation and their methods of use with at least one pharmaceutically acceptable excipient, which is devoi...

A process for the preparation of Solifenacin composition comprising the steps of: a) dispersing the Solifenacin or its pharmaceutically acceptable salts thereof into the solvent; b) preparing a dry blend by mixing pharmaceutically acceptable excipients; c) adding the granulating fluid to the dry blend to obtain gran...

The present invention relates to a pharmaceutical composition comprising Tamsulosin and its pharmaceutically acceptable salts thereof. The present invention specifically relates to controlled release pharmaceutical composition comprising Tamsulosin having formula-I and a process for the preparation thereof. ...

A pharmaceutical composition comprising an uncoated immediate release dosage form comprising Tianeptine and its pharmaceutically acceptable salts.

1) A novel process for the preparation of compound of formula VI: wherein, Rjand R2 represents Hydrogen, Cito C4 alkyl, benzyl, Substituted benzyl, reacting the compound of Formula-IV with chlorinating agent to yield compound of formula V; which is further reacted with toluene to obtain the compound of formula VI,...

A pharmaceutical composition comprising a high drug load of Fenofibrate, wherein the Fenofibrate is present in more than 70% by weight of total composition.

The invention relates to Ferric organic compound containing compositions. The pharmaceutical compositions of the invention which include Ferric citrate as the active ingredient, a disintegrant, and one or more pharmaceutically acceptable excipients

The invention relates to oral pharmaceutical compositions of ferric citrate comprising dry granulation, wherein ferric citrate is combined with dry binder or disintegrant, and a lubricant, which is roller compacted, and then mixed with extra granular material comprising disintegrant, and lubricant, wherein the amoun...

The present invention relates to an improved process for the preparation of highly pure Propiomazine Maleate of formula-I.

The present invention relates to one pot process for the preparation of 4-(l,2-dihydro-2-oxobenzo[d]imidazol-3-yl)butanoic acid of Formula-1, which is a key intermediate and its use in the preparation of Zilpaterol, which comprises condensation of methyl-4-chloro butyrate with 1-(prop-l-en-2-yl)-lH-benzo[d]iirudazol...

An improved process for preparation of ferric citrate, wherein the process involves reacting ferric salt with ammonium hydroxide to adjust the pH to 7.2 to 7.8 at a temperature of 25-35°c to form ferric hydroxide, which is then added citric acid at a temperature of 75-85°c to yield ferric citrate in solution and a...